Literature DB >> 11325634

Ribozyme gene therapy: applications for molecular medicine.

A S Lewin1, W W Hauswirth.   

Abstract

RNA enzymes--ribozymes--are being developed as treatments for a variety of diseases ranging from inborn metabolic disorders to viral infections and acquired diseases such as cancer. Ribozymes can be used both to downregulate and to repair pathogenic genes. In some instances, short-term exogenous delivery of stabilized RNA is desirable, but many treatments will require viral-mediated delivery to provide long-term expression of the therapeutic catalyst. Current gene therapy applications employ variations on naturally occurring ribozymes, but in vitro selection has provided new RNA and DNA catalysts, and research on trans-splicing and RNase P has suggested ways to harness the endogenous ribozymes of the cell for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325634     DOI: 10.1016/s1471-4914(01)01965-7

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  23 in total

1.  Ribozyme-based gene-inactivation systems require a fine comprehension of their substrate specificities; the case of delta ribozyme.

Authors:  Lucien Junior Bergeron; Jonathan Ouellet; Jean-Pierre Perreault
Journal:  Curr Med Chem       Date:  2003-12       Impact factor: 4.530

2.  Ribozymes: catalytic RNAs that cut things, make things, and do odd and useful jobs.

Authors:  Nils G Walter; David R Engelke
Journal:  Biologist (London)       Date:  2002-10

3.  Hammerhead ribozyme-mediated knockdown of mRNA for fibrotic growth factors: transforming growth factor-beta 1 and connective tissue growth factor.

Authors:  Paulette M Robinson; Timothy D Blalock; Rong Yuan; Alfred S Lewin; Gregory S Schultz
Journal:  Methods Mol Biol       Date:  2012

Review 4.  Convergent evolution of twintron-like configurations: One is never enough.

Authors:  Mohamed Hafez; Georg Hausner
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

5.  Small molecule control of pre-mRNA splicing.

Authors:  Brenton R Graveley
Journal:  RNA       Date:  2005-01-20       Impact factor: 4.942

6.  Development and comparison of procedures for the selection of delta ribozyme cleavage sites within the hepatitis B virus.

Authors:  Lucien Junior Bergeron; Jean-Pierre Perreault
Journal:  Nucleic Acids Res       Date:  2002-11-01       Impact factor: 16.971

7.  A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.

Authors:  Edwin H Yau; Mark C Butler; Jack M Sullivan
Journal:  Exp Eye Res       Date:  2016-05-25       Impact factor: 3.467

8.  Soft Interactions with Model Crowders and Non-canonical Interactions with Cellular Proteins Stabilize RNA Folding.

Authors:  May Daher; Julia R Widom; Wendy Tay; Nils G Walter
Journal:  J Mol Biol       Date:  2017-11-08       Impact factor: 5.469

9.  An animal model of PDH deficiency using AAV8-siRNA vector-mediated knockdown of pyruvate dehydrogenase E1α.

Authors:  Carolyn Ojano-Dirain; Lyudmyla G Glushakova; Li Zhong; Sergei Zolotukhin; Nicholas Muzyczka; Arun Srivastava; Peter W Stacpoole
Journal:  Mol Genet Metab       Date:  2010-07-15       Impact factor: 4.797

10.  Site-Selective RNA Splicing Nanozyme: DNAzyme and RtcB Conjugates on a Gold Nanoparticle.

Authors:  Jessica R Petree; Kevin Yehl; Kornelia Galior; Roxanne Glazier; Brendan Deal; Khalid Salaita
Journal:  ACS Chem Biol       Date:  2017-12-19       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.